Obesity Treatment Insights

• Amazon Pharmacy, CVS and Walmart are competing to fill Medicare GLP-1 prescriptions at a flat $50 monthly copay under the new Bridge program.
• The...

Real-world data show bariatric surgery delivers far greater total weight loss than GLP-1 receptor agonists.

• Semaglutide: 5.4–7.4% TWL; tirzepatide:...

A scoping review of 23 studies concludes GLP-1RA monotherapy does not affect energy expenditure independent of weight loss. Eight studies found...

Shingo Kajimura's research targets cold adaptation pathways in fat cells to convert stored fat into heat and raise metabolic rate. This could complement existing appetite-suppressing medications through a dual-action strategy.

Even after hunger and appetite sensations return around week 40, semaglutide users still consume 24-30% fewer calories than placebo recipients...

Immunwork's TE-8105 uses a novel dual fatty acid (2FA) platform attaching both C16 and C18 chains to lysine-26 via a multiarm linker, creating denser...

GLP-1 receptor agonists improve glycemic control and promote weight loss through mechanisms including enhanced glucose-dependent insulin secretion.

Lilly now accepts physician applications for retatrutide early access in refractory obesity cases with at least two major complications after failing...

RM-718 produced an 11.6% BMI reduction at 16 weeks in acquired hypothalamic obesity, a rare, hard-to-treat condition.

• Safety differentiation: Only...

Bariatric surgery is integrating with GLP-1 drugs in a multimodal model rather than facing replacement.

• Patient-centered integration: Experts at...

New international consensus guidelines fill a critical evidence void for incretin-based medications in women of childbearing age.

• Key gap filled:...

This pioneering MBSAQIP analysis fills a major data gap by examining metabolic and bariatric surgery outcomes in non-binary individuals for the first...

Sleeve gastrectomy is an effective and safe obesity treatment, delivering 20%-25% TBWL at 12 months with a favorable safety profile.

LSU researchers advocate replacing metabolically healthy/unhealthy labels with preclinical obesity (excess fat without current harm) and clinical...

Eli Lilly moved from a single 79-year-old patient's compassionate use in June to a formal expanded access program announced August 3. The program...

Bariatric procedures are extending to older adults and endometrial cancer patients with severe obesity.

• Roux-en-Y gastric bypass in 1013 older...

Three emerging therapies target gaps in current GLP-1 treatments through novel mechanisms and practical advantages.

• WVE-007 RNAi advances to Phase...

Obesity is no longer framed as a simple willpower deficit but as a chronic, relapsing disease driven by genetics, neurobiology and environment. Modern...

The American Gastroenterological Association defines 3% weight loss as the minimally important difference for medication effectiveness beyond...

Wegovy produced the strongest safety signal for rare optic nerve injury among semaglutide products, with a reporting odds ratio of 74.89 and men...